A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
10/2002
10/29/2002	US6471959 Human transferase
10/29/2002	CA2263455C Liposomes containing a cisplatin compound
10/29/2002	CA2215922C Methods for screening compounds for estrogenic activity
10/29/2002	CA2107471C Fluorine-containing vitamin d3 analogues
10/29/2002	CA2088128C Salts of glucopyranose derivatives and its intermediate
10/29/2002	CA2063431C Receptors for fibroblast growth factors
10/29/2002	CA2060034C Tumour growth-inhibiting somatostatin analogues, pharmaceutical compositions containing them and process for preparing same
10/28/2002	WO2001082909A2 2-acyl indol derivatives and their use as anti-tumour agents
10/28/2002	CA2407677A1 2-acyl indol derivatives and their use as anti-tumour agents
10/25/2002	WO2001078652A2 Methods for drug discovery, disease treatment, and diagnosis using metabolomics
10/25/2002	CA2443806A1 Methods for drug discovery, disease treatment, and diagnosis using metabolomics
10/24/2002	WO2002083950A1 Methods and compositions for treating cardiovascular disease using 10218
10/24/2002	WO2002083945A2 Diagnosis and treatment of cancer: i
10/24/2002	WO2002083928A2 Nucleid acid and corresponding protein entitled 158p3d2 useful in treatment and detection of cancer
10/24/2002	WO2002083921A2 Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
10/24/2002	WO2002083919A2 Nucleic acid and corresponding protein entitled 184p1e2 useful in treatment and detection of cancer
10/24/2002	WO2002083917A2 Nucleic acid and corresponding protein entitled 161p5c5 useful in treatment and detection of cancer
10/24/2002	WO2002083916A2 Nucleic acid and corresponding protein entitled 162p1e6 useful in treatment and detection of cancer
10/24/2002	WO2002083899A1 Cancer-associated genes
10/24/2002	WO2002083898A1 Full-length human cdnas encoding potentially secreted proteins
10/24/2002	WO2002083874A2 Endothelial cell expression patterns
10/24/2002	WO2002083873A2 Enzymes
10/24/2002	WO2002083870A2 Pufa polyketide synthase systems and uses thereof
10/24/2002	WO2002083866A2 Repeat sequences of the ca125 gene and their use for diagnostic and therapeutic interventions
10/24/2002	WO2002083860A2 Nucleic acid and corresponding protein entitled 151p3d4 useful in treatment and detection of cancer
10/24/2002	WO2002083847A2 Cdna encoding the human alpha2 delta4 calcium channel subunit
10/24/2002	WO2002083841A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
10/24/2002	WO2002083738A1 Cyclic single strand trispecific antibody
10/24/2002	WO2002083735A1 Novel receptor protein and dna thereof
10/24/2002	WO2002083733A2 Polynucleotides and polypeptides of the ifnalpha-6 gene
10/24/2002	WO2002083727A2 Nucleic acid sequences of hyperplasies and tumors of the thyroid
10/24/2002	WO2002083712A2 Transporters and ion channels
10/24/2002	WO2002083709A2 Kinases and phosphatases
10/24/2002	WO2002083704A1 Vascular endothelial growth factor 2
10/24/2002	WO2002083696A2 Novel cyclo azaphospha hydrocarbons
10/24/2002	WO2002083675A2 Inhibitors of akt activity
10/24/2002	WO2002083669A1 Tropane alkaloid multidrug resistance inhibitors from erythroxylum pervillei and use of the same
10/24/2002	WO2002083668A1 Isoxaxole derivatives as inhibitors of src and other protein kinases
10/24/2002	WO2002083667A2 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
10/24/2002	WO2002083654A1 Triazinyl amide derivatives as angiogenesis inhibitors
10/24/2002	WO2002083653A1 Triazinyl acrylamide derivatives as kinase inhibitors
10/24/2002	WO2002083627A2 Ligands des integrins avss6
10/24/2002	WO2002083624A1 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands
10/24/2002	WO2002083186A1 Nuclear receptor-mediated introduction of a pna into cell nuclei
10/24/2002	WO2002083180A1 Elongated and multiple spacers in activatible prodrugs
10/24/2002	WO2002083179A2 Fusion proteins
10/24/2002	WO2002083173A1 Use of an histone deacetylase inhibitor for the treatment of diseases associated with an hpv infection
10/24/2002	WO2002083171A2 Cancer treatment by using fap-alpha specific antibodies
10/24/2002	WO2002083170A1 Vaccines including as an adjuvant type 1 ifn and processes related thereto
10/24/2002	WO2002083166A1 Interferon-polymer complexes and medicinal use thereof
10/24/2002	WO2002083159A1 Palliative effects of morinda citrifolia oil and juice
10/24/2002	WO2002083158A1 Method for preparing an extract of ginkgo biloba leaves highly enriched in active principles
10/24/2002	WO2002083155A1 Use of sulfated bacterial polysaccharides suitable for the inhibition of angiogenesis
10/24/2002	WO2002083154A1 Use of cationic dextran derivatives for protecting dose-limiting organs
10/24/2002	WO2002083152A1 Activation of natural killer cells by adenosine a3 receptor agonists
10/24/2002	WO2002083143A1 Cxcr3 antagonists
10/24/2002	WO2002083142A1 Novel use of arylethenesulfonamide derivative
10/24/2002	WO2002083138A1 Inhibitors of akt activity
10/24/2002	WO2002083123A1 Aurones as telomerase inhibitors
10/24/2002	WO2002083117A1 Toluene sulfonamide-containing anti-tumor composition and method of use thereof
10/24/2002	WO2002083115A1 Treatment of disorders secondary to organic impairments
10/24/2002	WO2002083114A1 Pharmaceutical compositiong or preventing and treating cancer and treating an inflammation
10/24/2002	WO2002083074A2 Methods for the treatment of hepatic disorders
10/24/2002	WO2002083067A2 Prodrugs via acylation with cinnamate
10/24/2002	WO2002083065A2 Peptide antiangiogenic drugs
10/24/2002	WO2002083064A2 A method of treating cancer
10/24/2002	WO2002083063A2 Method of improving systemic exposure of subcutaneously administered therapeutic proteins
10/24/2002	WO2002083060A2 Use of amino acid transporter atb0,+ as a delivery system for drugs and prodrugs
10/24/2002	WO2002083030A2 Bifunctional energy-reversible acyl-compositions
10/24/2002	WO2002067999A3 Actinium-225 complexes and conjugates for targeted radiotherapy
10/24/2002	WO2002066451A3 1,2-diphenyl-1-naphthyl ethene derivatives, analogs and use thereof
10/24/2002	WO2002066428A3 Non-steroidal estrogen receptor ligands
10/24/2002	WO2002066035A3 Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators
10/24/2002	WO2002066019A3 Cancer treatment
10/24/2002	WO2002060931A3 A fimbria-like gene in bifidobacteria
10/24/2002	WO2002057226A9 68730 and 69112 protein kinase molecules and uses therefor
10/24/2002	WO2002051848A3 Sulfamidothienopyrimidines and the use of the same as phosphodiesterase v inhibitors
10/24/2002	WO2002050065A3 Pyrazole compounds useful as protein kinase inhibitors
10/24/2002	WO2002040038A3 M. tuberculosis chaperonin 10 and uses thereof
10/24/2002	WO2002024610A3 Method for producing an antineoplastic
10/24/2002	WO2002022777A3 Cellular genes involved in oncogenesis, products of said genes and their diagnostic and therapeutic uses
10/24/2002	WO2002022626A8 Combretastatin a-4 phosphate prodrug salts with nitrogen-containing compounds
10/24/2002	WO2002017935A3 A method of transplantation using chemotherapy-treated allogeneic cells that enhance immune responses without graft versus host disease
10/24/2002	WO2002006462A3 Methylated nucleotide regulation of upa gene expression
10/24/2002	WO2002000650A3 Novel compounds possessing antibacterial, antifungal or antitumor activity
10/24/2002	WO2001077375A8 Diagnosis of diseases associated with gene regulation
10/24/2002	WO2001076568B1 Use of 13-hode as a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
10/24/2002	WO2001072315A9 Emulsion containing a plant extract, method for producing said emulsion and for obtaining a plant extract
10/24/2002	WO2001068911A8 Diagnosis of diseases associated with the cell cycle
10/24/2002	WO2001068676A3 Lhrh-antagonists, production and use thereof as medicament
10/24/2002	WO2001068135A9 Compositions and methods for affecting osteogenesis
10/24/2002	WO2001062793A9 Estrogen receptor beta variants and methods of detection thereof
10/24/2002	WO2001059103A9 Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
10/24/2002	WO2001059073A9 Cytotoxic t lymphocytes activated by dendritic cell hybrids
10/24/2002	WO2001055337A3 Methods and materials relating to carcinoembryonic antigen-like (cea-like) polypeptides and polynucleotides
10/24/2002	WO2001053299A9 Compounds of the saframycin-ecteinascidin series, uses, and synthesis thereof
10/24/2002	WO2001021135A3 Polymer conjugates of ara-c and ara-c derivatives
10/24/2002	US20020156292 Anticancer agents
10/24/2002	US20020156264 And method of using the carboxypeptidase polypeptides and polynucleotides as a target for diagnosis and treatment in carboxypeptidase-related disorders
10/24/2002	US20020156261 Wherein secondary structure disintegrates upon attachment of the oligonucleotide to a target nucleic acid; anticarcenogenic agents, treatment of Ewing's sarcoma

1 ... 1647 1648 1649 1650 1651 1652 1653 1654 1655 1656 1657 1658 1659 1660 1661 1662 1663 1664 1665 1666 1667 ... 2211